Get the Most Complete "Everything But the Kitchen Sink" Hair Loss Solution on the Market Today... with Minoxidil 4.5%, L'Oreal's Aminexil SP94, the Newly Discovered Anti-Stress Hormone Astressin-B, Retinol, Nanosomes, Ketoconazole, Copper Peptides, Emu Oil Caffeine, and Lots MORE!
The results of a recent study conducted by DS Laboratories showed that its new Spectral.DNC hair regrowth treatment was effective in the promotion of hair growth and in the cessation of hair loss in males suffering with androgenetic alopecia. Subjects were also evaluated for adverse events and it was shown that this treatment is safe for use.
The primary goal of the study was to assess the safety and effectiveness of Spectral.DNC in the promotion of hair growth and in the cessation of hair loss in males. Efficacy in females has not been established. Among its ingredients, Spectral.DNC contains Minoxidil 5% solution. Women are advised to check with their health care provider before using this treatment.
The study was designed as randomized, double-blind trial conducted at DS Laboratories's headquarters in Miami Beach, FL. Thisstudy was not placebo-controlled. However, the application of the Spectral.DNC solution was done by the lab technicians in order to observe the efficacy under proper use. Therefore study participants had to visit the DS Labs's office twice per day, every day for 90 days including weekends and holidays. The solution was kept in a white container simply marked “Solution A”. Neither the lab technician nor the study participants knew what was being applied to their scalps. Global photographs were taken at baseline and then again at 90 days.
The study population included males between the ages of 25 and 55 years with who had been experiencing active hair loss. Subjects who were primarily number 3 and 4 on the Norwood Scale (insert picture of Norwood Scale) were favored for the study due to the possibility of faster results. A total of 15 male subjects completed the study.
Prior to beginning the study subjects had their scalp evaluated for dermatological conditions that could potential disqualify them. All volunteers had healthy scalps and were enrolled in the study. A global photograph was taken from the crown area and a second photograph was taken of the top of the head to track frontal areas. Subjects then had to appear at the office twice every day for the technician to apply the solution to the scalp under controlled conditions. The improvements in the target site were observed using high resolution photography.
Below are examples of effectiveness that seen at the completion of the study. The photographs show the image at baseline and then a secondary image collected at 90 days. No adverse events were reported or observed.
Table 1 summarizes the subjects own assessment of overall hair regrowth mean change from baseline in %. 14 out of 15 subjects had significant increase in mean terminal hair growth. Only 1 subject did not respond to the treatment. Fully 80% of test subjects noted moderate to dense hair growth:
Subjects Assessment of Overall Hair Regrowth
Mean Change From Baseline in %
No Growth: 6.7%
Minimal Growth: 20%
Moderate Growth: 53.5%
Dense Growth: 26.7%
For more information on or to order the Spectral DNC Pack with Astressin-B, click on the image below...